4//SEC Filing
Dumas Jacques 4
Accession 0001209191-18-006210
CIK 0001373707other
Filed
Jan 30, 7:00 PM ET
Accepted
Jan 31, 4:24 PM ET
Size
9.3 KB
Accession
0001209191-18-006210
Insider Transaction Report
Form 4
Dumas Jacques
Chief ScientificOfficer
Transactions
- Sale
Common Stock
2018-01-30$6.22/sh−8,750$54,425→ 0 total - Exercise/Conversion
Common Stock
2018-01-30$3.69/sh+8,750$32,288→ 8,750 total - Exercise/Conversion
Employee Stock Option (Right to Buy)
2018-01-30−8,750→ 105,000 totalExercise: $3.69Exp: 2027-01-29→ Common Stock (8,750 underlying)
Footnotes (3)
- [F1]The exercise and sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 16, 2017.
- [F2]The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $6.14 to $6.32 per share. The reporting person undertakes to provide, upon request, to the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.
- [F3]Vests as to 6.25% of the shares on 4/30/2017 and further vests as to an additional 6.25% of the original grant at the end of each successive three-month period thereafter until 1/31/2021.
Documents
Issuer
TETRAPHASE PHARMACEUTICALS INC
CIK 0001373707
Entity typeother
Related Parties
1- filerCIK 0001598640
Filing Metadata
- Form type
- 4
- Filed
- Jan 30, 7:00 PM ET
- Accepted
- Jan 31, 4:24 PM ET
- Size
- 9.3 KB